Florence T Bourgeois

Biographic Data

ID6066141
NAMEFlorence T Bourgeois
GIVEN NAMESFlorence T
FAMILY NAMEBourgeois
SIGNATUREBOURGEOIS F T
AFFILIATIONSBoston Children's Hospital
ORCID0000-0001-7798-4560
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS1
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2013
LATEST PUBLICATION YEAR2024
H-INDEX1

  • The challenges of regulatory pluralism

    Open AccessSandra Gillner, Katharina Blankart et al.ARTICLEHealth Policy2024

    Countries with small and/or less-resourced regulatory authorities that operate outside of a larger medical product regulatory system face a regulatory strategy dilemma. These countries may rely on foreign well-resourced regulators by recognising the regulatory decisions of large systems and following suit (regulatory reliance); alternatively, such countries may extend formal decision recognition to regulators in multiple other jurisdictions with …

  • Enrollment of Pediatric Patients in Covid-19 Interventional Trials

    Open AccessMei‐Sing Ong, Mei-Sing Ong et al.ARTICLEJAMA Health Forum2023

    This cross-sectional study uses information gathered from ClinicalTrials.gov to assess the inclusion of children in COVID-19 interventional trials conducted in the US

  • Personal Protective Equipment for Covid-19

    Michael S Sinha, Florence T Bourgeois et al.ARTICLEAmerican Journal of Public Health2020Cited by: 1References: 3

  • Industry influence in evidence production

    Adam G Dunn, Florence T Bourgeois et al.ARTICLEJournal of Epidemiology and…2013References: 18

    In light of a number of recent drug development and marketing controversies, there is increasing public focus on the role of industry in determining how drugs are used.1–3 New methods that evaluate how funding has influenced the design, reporting, and synthesis of evidence from clinical trials have identified the breadth of industry involvement in evidence production. The downstream effects on public health remain difficult to quantify. In order …